Mort Collins has become a member of the board of directors of Formula Pharmaceuticals, an oncology drug development company based in Pennsylvania. Formula is researching novel therapeutics that target both cancer stem cells and various minimal residual disease settings.

Collins is founder and general partner of Battelle Ventures and Innovation Valley Partners, New Jersey-based funds that create and accelerate the development of early-stage technology companies. In addition, Collins was the founder of Data Science Ventures, Inc. (DSV) and managing partner in four DSV partnerships that specialized in early-stage financing of various high-technology companies. In 1997, Collins became a special limited partner of Cardinal Partners, successor of the DVS partnerships.

Collins received his undergraduate degree in chemical engineering from the University of Delaware and his Ph.D. from Princeton in 1963, also in chemical engineering. Collins serves as a member of Princeton Engineering’s Leadership Council and as a member of Princeton’s Graduate School Advisory Council.